Emilie Mamessier

Responsable d'équipe CR1 INSERM, HDR
Publications
Aug 2019 Cancers

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.

de Nonneville A, Finetti P, Adelaide J, Lambaudie É, Viens P, Gonçalves A, Birnbaum D, Mamessier E, Bertucci F

Jun 2019 JCI insight

Sensitive and easy screening for circulating tumor cells by flow cytometry.

Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, Finetti P, Gilabert M, Raoul JL, Birnbaum D, Acquaviva C, Mamessier E

Nov 2020 Journal for immunotherapy of cancer

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.

Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG

May 2021 Oncoimmunology

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.

Bertucci F, Boudin L, Finetti P, Van Berckelaer C, Van Dam P, Dirix L, ViensP, Gonçalves A, Ueno NT, Van Laere S, Birnbaum D, Mamessier E

Sep 2020 Cancers

Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?

Aulas A, Finetti P, Lyons SM, Bertucci F, Birnbaum D, Acquaviva C, Mamessier E

Apr 2020 Hepatology (Baltimore, Md.)

Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG

Jan 2020 The British journal of surgery

Prognostic impact of tumour-infiltrating lymphocytes and cancer-associated fibroblasts in patients with pancreatic adenocarcinoma of the body and tail undergoing resection.

Delayre T, Guilbaud T, Resseguier N, Mamessier E, Rubis M, Moutardier V, Fara R, Berdah SV, Garcia S, Birnbaum DJ

Jun 2019 Cancers

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease.

Mari R, Mamessier E, Lambaudie E, Provansal M, Birnbaum D, Bertucci F, Sabatier R

Apr 2019 Cancers

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors.

Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E

Jan 2019 Clinical cancer research : an official journal of the American Association for Cancer Research

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX

Nov 2018 British journal of cancer

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.

Bertucci F, Finetti P, Simeone I, Hendrickx W, Wang E, Marincola FM, Viens P, Mamessier E, Ceccarelli M, Birnbaum D, Bedognetti D

Apr 2018 Biochimica et biophysica acta. Reviews on cancer

Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.

Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E

Feb 2018 Annals of translational medicine

CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.

Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F